The promise of precision medicine is conditioned on knowing the vulnerabilities of a given tumor. The Witkiewicz-Knudsen Lab has been active through the years in defining the genetic makeup of tumors, building patient-derived models to test hypotheses and using sophisticated approaches to interrogate clinical tissue specimens.
We are currently developing new approaches to coordinately investigate features of signaling and cell cycle coordination in the tumor, while defining features of the microenvironment. Parallel studies are using computational approaches to direct the use of CDK inhibitors and other therapeutic modalities moving forward.
See the science
- Adams TA, et al. Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. Mod Pathol. 2018 Feb;31(2):288-298. doi: 10.1038/modpathol.2017.126.
- Knudsen ES, Witkiewicz AK. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends Cancer. 2017 Jan;3(1):39-55. doi: 10.1016/j.trecan.2016.11.006.
Contact the Witkiewicz-Knudsen Lab
Department of Molecular and Cellular Biology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263